title: Standardization of a Protocol for Obtaining Platelet Rich Plasma from blood Donors; a Tool for Tissue Regeneration Procedures.
abstract: BACKGROUND
  To develop a protocol for obtaining autologous platelet rich plasma in healthy individuals and to determine the concentration of five major growth factors before platelet activation. This protocol could be integrated into the guidelines of good clinical practice and research in regenerative medicine.
  
  
  METHODS
  Platelet rich plasma was isolated by centrifugation from 38 healthy men and 42 women ranging from 18 to 59 years old. The platelet count and quantification of growth factors were analyzed in eighty samples, stratified for age and gender of the donor. Analyses were performed using parametric the t-test or Pearson's analysis for non-parametric distribution. P < 0.05 was considered statistically significant.
  
  
  RESULTS
  Our centrifugation protocol allowed us to concentrate basal platelet counts from 1.6 to 4.9 times (mean = 2.8). There was no correlation between platelet concentration and the level of the following growth factors: VEGF-D (r = 0.009, p = 0.4105), VEGF-A (r = 0.0068, p = 0.953), PDGF subunit AA (p = 0.3618; r = 0.1047), PDGF-BB (p = 0.5936; r = 0.6095). In the same way, there was no correlation between donor gender and growth factor concentrations. Only TGF-β concentration was correlated to platelet concentration (r = 0.3163, p = 0.0175).
  
  
  CONCLUSIONS
  The procedure used allowed us to make preparations rich in platelets, low in leukocytes and red blood cells, and sterile. Our results showed biological variations in content of growth factors in PRP. The factors influencing these results should be further studied.
authors.forename: Lina Andrea
authors.initials: LA
authors.lastname: Gómez
authors.forename: Magally
authors.initials: M
authors.lastname: Escobar
authors.forename: Oscar
authors.initials: O
authors.lastname: Peñuela
mesh_terms: D000293:Adolescent; D000328:Adult; D000077214:Becaplermin; D001782:Blood Donors; D002498:Centrifugation / Q000592:standards; D002985:Clinical Protocols / Q000592:standards*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood; D064368:Healthy Volunteers; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D053657:Platelet-Rich Plasma / Q000737:chemistry / Q000166:cytology; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood; D011786:Quality Control; D012015:Reference Standards; D044968:Regenerative Medicine / Q000379:methods / Q000592:standards*; D016212:Transforming Growth Factor beta / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D042643:Vascular Endothelial Growth Factor D / Q000097:blood; D055815:Young Adult
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D016212:Transforming Growth Factor beta; C467484:VEGFA protein, human; C579459:VEGFD protein, human; D042461:Vascular Endothelial Growth Factor A; D042643:Vascular Endothelial Growth Factor D; C075278:platelet-derived growth factor A; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin